A Phase II, Single Institution, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of a Single Agent Dasatinib (Sprycel®) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Study Status
Open to Enrollment
Study Description
The purpose of this study is to determine the efficacy of the drug dasatinib in patients with diffuse large B-cell lymphoma who have progressed or relapsed since they received previous therapy.
The Treatment Phase consists of single agent dasatinib 100mg once daily on Days 1 through 28, every 28 days (28 day cycles). Patients may continue participation in the Treatment Phase of the study until disease progression or unacceptable adverse experiences develop.
Click here to visit our lymphoma blog.
Disease Status and/or Stage
Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsor
Weill Cornell Medical College
Key Eligibility
- Men and women age 18 and older
- Histolologic diagnosis of diffuse large B-cell lymphoma (DLBCL)
- Progressed or relapsed since most recent therapy
- Must have received at least one prior combination chemotherapy regimen; there is no limit to the number of prior therapies
- More detailed eligibility criteria to be discussed when you contact the study team
Principal Investigator
Contact
- June Greenberg, RN
- (212) 746-2651
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
